Business Wire

BearingPoint//Beyond Announces its Infonova Digital Business Platform Is Now 5G-ready

4.12.2019 11:00:00 EET | Business Wire | Press release

Share

BearingPoint//Beyond today announced that its Infonova Digital Business Platform is now 5G-ready, enabling Communication Service Providers (CSPs) around the world to create, experiment, launch and monetize new 5G offerings at speed and at scale. The Infonova platform has already been selected by major CSPs, including NTT Group and Tata Communications.

As 5G rolls out across the globe, new opportunities emerge for CSPs and their partners to develop new business models, use cases and applications that make use of 5G’s high-speed, low latency and always-on mobile connectivity. However research has demonstrated that, in order to succeed in the multi-trillion dollar enterprise services market, CSPs must adopt leaner, more agile operations that prioritize experimentation, collaboration, innovation, and rapid time to market.

To monetize 5G at scale, CSPs must ensure that their operational and business support systems can meet four main requirements:

  • Orchestration and delivery of complex solutions spanning both different types of networks (e.g: 4G, Fiber,5G) and different sources of services (e.g. edge, AR, VR)
  • Flexibility in charging and monetization capabilities enabling CSPs to bundle and price anything from network slicing and consumer IoT, to industrial IoT solutions
  • The development of partner ecosystems enabling CSPs to truly co-invent and co-create joint solutions with multiple third parties that better fit customer needs
  • Increased operational agility and speed with cloud native solutions

The 5G-ready Infonova Digital Business Platform has been designed to deliver precisely these capabilities, enabling CSPs to:

  • Reduce risk by rapidly experimenting, launching and monetizing new offerings and scale with success, due to its SaaS delivery model
  • Achieve fast and simple integration with their business and operational landscape by using a comprehensive library of Open APIs and a flexible microservices and containerized architecture delivered in cloud native environments
  • Offer advanced charging and billing capabilities ready to support any pricing model, including network slicing offerings
  • Bundle anything with connectivity – especially important for consumer IoT, OTT services and enterprise solutions (e.g. Industrial IoT, Autonomous driving) – as a result of its flexible catalogue
  • Access comprehensive order management and service fulfillment functionalities, managing the challenge and complexity of dynamic 5G service activation, diversity of devices and network functions
  • Support multiple business partners on a single platform, allowing CSPs to easily and dynamically exchange offerings, orchestrate and monetize B2B2X, B2B, IoT marketplace, B2C and wholesale 5G use cases with an ecosystem of partners

“If CSPs are to capitalize on 5G opportunities – especially those presented by the multi-trillion-dollar enterprise services market - they need to start embracing digital business platforms. These platforms enable them to create new B2B2x business models with partner ecosystems, packaging 5G connectivity with devices, applications, IoT capabilities and AI into entirely new products and services,” said Angus Ward, CEO of BearingPoint//Beyond. “Our Infonova Digital Business Platform helps CSPs do just that. By using our platform, CSPs can roll out new, complex, partner-driven offerings quickly and reach new lucrative vertical sectors and customers.”

“IDC believes that multi-partner relationships are a growing domain in the digital world and will need platforms such as BearingPoint//Beyond’s digital business platform to orchestrate and monetize them effectively,” commented Mark Thomason, Research Director, IDC Digital Business Models and Monetization.

For more information on how BearingPoint//Beyond can help you monetize 5G, please click here.

- ENDS -

About BearingPoint//Beyond

BearingPoint//Beyond is a BSS and digital platform solution provider helping businesses to innovate and grow revenue in face of digital disruption.

Using the SaaS-based Infonova digital platform, BearingPoint//Beyond gives organizations the ability to experiment, launch and monetize new offerings at speed, with minimum risk and cost. Building connections between technologies and partners, enabling them to collaborate, co-innovate and expand their reach with an ecosystem of partners. Bringing them closer to their customers, helping you drive higher efficiency and automation, and becoming more agile in the face of competition.

BearingPoint//Beyond is part of BearingPoint.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

BearingPoint//Beyond home page: https://www.bearingpointbeyond.com
Homepage: www.bearingpoint.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact BearingPoint//Beyond
Michal Harris
Head of Marketing
Phone: + 44 (0)79 6637 1449
E-mail: michal.harris@bearingpoint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye